In last trading session, Atyr Pharma Inc (NASDAQ:ATYR) saw 2.12 million shares changing hands with its beta currently measuring 0.96. Company’s recent per share price level of $3.55 trading at $0.48 or 15.64% at ring of the bell on the day assigns it a market valuation of $297.99M. That closing price of ATYR’s stock is at a discount of -31.27% from its 52-week high price of $4.66 and is indicating a premium of 60.0% from its 52-week low price of $1.42. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.92 million shares which gives us an average trading volume of 1.18 million if we extend that period to 3-months.
Atyr Pharma Inc (NASDAQ:ATYR) trade information
Upright in the green during last session for gaining 15.64%, in the last five days ATYR remained trading in the green while hitting it’s week-highest on Friday, 03/07/25 when the stock touched $3.55 price level, adding 4.57% to its value on the day. Atyr Pharma Inc’s shares saw a change of -1.93% in year-to-date performance and have moved 12.70% in past 5-day. Atyr Pharma Inc (NASDAQ:ATYR) showed a performance of -5.84% in past 30-days. Number of shares sold short was 5.26 million shares which calculate 4.17 days to cover the short interests.
Atyr Pharma Inc (ATYR) estimates and forecasts
This year revenue growth is estimated to fall -53.05% from the last financial year’s standing.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 43.36% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 3.09% while estimates for its earnings growth in next 5 years are of 8.29%.
Atyr Pharma Inc (NASDAQ:ATYR)’s Major holders
Insiders are in possession of 2.16% of company’s total shares while institution are holding 66.48 percent of that, with stock having share float percentage of 67.94%. Investors also watch the number of corporate investors in a company very closely, which is 66.48% institutions for Atyr Pharma Inc that are currently holding shares of the company.
